CSL Plasma and Terumo Blood and Cell Technologies (Terumo BCT) have completed the nationwide rollout of a new plasma donation system across CSL Plasma centers in the United States. This milestone aims to enhance donor care and improve access to plasma-derived therapies for patients in need. The Rika Plasma Donation System, which has been installed…more
Terumo Blood and Cell Technologies (Terumo BCT) reported regulatory approvals in 14 Latin American countries for its Spectra Optia Apheresis System, allowing for new treatment options for sickle cell disease, Guillain-Barré syndrome and myasthenia gravis. This development signifies a major step toward enhancing access to therapies for patients with rare and chronic diseases in the…more
Aclarion Inc. has appointed Greg Gould as its new chief financial officer, effective immediately. Gould comes to Aclarion with more than 30 years of experience in public and private companies. He succeeds John Lorbiecki, who has announced his retirement after establishing a strong financial foundation for the company, Aclarion stated in a press release. Aclarion…more
Highridge Medical acquired several spine surgery products from Accelus, including the FlareHawk and Toro expandable interbody fusion systems and the LineSider pedicle screw system. The move is intended to strengthen Highridge’s presence in the growing market for expandable spinal implants. The acquired products feature proprietary designs, such as Accelus’s Adaptive Geometry, aimed at improving surgical…more
Terumo Blood and Cell Technologies (Terumo BCT) and PwC Belgium have partnered to improve access to advanced cell and gene therapies in Europe. This joint effort seeks to address existing barriers that prevent patients from receiving cutting-edge medical treatments. The partnership will kick off with an event in Brussels on Dec. 11, 2025, where industry…more
PharmaJet Inc. has been awarded a tender to support the first large-scale implementation of intradermal (ID) polio immunization in Afghanistan. The campaign, part of efforts to eradicate poliovirus in the region, is expected to begin in August 2025. The campaign will use Golden-based PharmaJet’s Tropis ID delivery system to administer fractional doses of inactivated polio…more
Ignite Proteomics, a subsidiary of IMAC Holdings, has announced a one-year collaboration with Vanderbilt University Medical Center (VUMC) aimed at enhancing the understanding of how breast cancer cells avoid detection by the immune system. This partnership will utilize VUMC’s clinical samples to characterize specific protein-signaling pathways associated with breast tumors. As part of the collaboration,…more
Aclarion Inc. (Nasdaq: ACON), a Broomfield-based healthcare technology company, reported a 132% year-over-year increase in scan volume for its flagship product, Nociscan, from Q2 2024 to Q2 2025. This marks the company’s first time achieving two consecutive quarters of scan growth. Nociscan uses proprietary AI algorithms and magnetic resonance spectroscopy to help physicians identify the…more
PharmaJet Inc. has signed a Memorandum of Understanding (MOU) with the Egyptian Unified Procurement Authority and EVA Pharma to explore needle-free delivery of vaccines in Egypt’s routine immunization program. This agreement was formalized during the African Health ExCon health care conference held in Cairo on June 26. The collaboration aims to integrate needle-free technology for…more
Cerapedics Inc. successfully treated the first U.S. patient using its newly approved bone graft designed to accelerate lumbar fusion. This marks a significant milestone following the approval from the U.S. Food and Drug Administration (FDA) for the PearlMatrix P-15 Peptide Enhanced Bone Graft. The procedure was carried out at AdventHealth Avista in Louisville, Colo., by…more
Aclarion Inc. enrolled the first patient in its CLARITY trial, aimed at assessing the impact of its Nociscan technology on surgical treatments for chronic low back pain. The initial participant was enrolled at the Texas Back Institute, recognized for its advancements in spine care. The CLARITY trial is a randomized clinical study designed to evaluate…more
PharmaJet Inc. has partnered with Immuno Cure to develop a needle-free HIV therapeutic DNA vaccine. The agreement, signed on June 16, 2025, during the BIO International Convention in Boston, will utilize PharmaJet’s Tropis system in a human clinical trial for their ICVAX vaccine. This collaboration follows the success of an earlier Phase 1 trial of…more